45 Healthcare Resource Utilization and Costs Among Patients Receiving Cangrelor or Glycoprotein IIb/IIIa Inhibitors During Percutaneous Coronary Intervention in the United States | Synapse
March 31, 2026
45 Healthcare Resource Utilization and Costs Among Patients Receiving Cangrelor or Glycoprotein IIb/IIIa Inhibitors During Percutaneous Coronary Intervention in the United States
Key Points
Key points are not available for this paper at this time.